WO2000022124A3 - Methods and compositions to induce antitumor response - Google Patents

Methods and compositions to induce antitumor response Download PDF

Info

Publication number
WO2000022124A3
WO2000022124A3 PCT/US1999/021454 US9921454W WO0022124A3 WO 2000022124 A3 WO2000022124 A3 WO 2000022124A3 US 9921454 W US9921454 W US 9921454W WO 0022124 A3 WO0022124 A3 WO 0022124A3
Authority
WO
Grant status
Application
Patent type
Prior art keywords
cells
compositions
present invention
dendritic
induce
Prior art date
Application number
PCT/US1999/021454
Other languages
French (fr)
Other versions
WO2000022124A2 (en )
Inventor
Drake M Laface
Original Assignee
Canji Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52Cytokines; Lymphokines; Interferons
    • C07K14/521Chemokines
    • C07K14/523Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515Animal cells
    • A61K2039/5154Antigen presenting cells [APCs], e.g. dendritic cells, macrophages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00Uses of viruses
    • C12N2799/02Uses of viruses as vector
    • C12N2799/021Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus

Abstract

(57) Abstract The present invention provides compositions which are engineered to induce killing of tumor cells and concomitantly mobilize, differentiate, activate and attract dendritic cells through the expression of cytokines and dendritic cell chemoattractants. The present invention induces multiple stages of dendritic cell differentiation, activation and migration in vivo using gene therapy delivery systems. Moreover, this invention describes the rational design of utilizing viral vectors (preferred vector is rAd) for multiple administrations of targeted delivery to dendritic cells which can promote differentiation and activation of the transduced dendritic cells (thus augmenting in vivo stimulation of T cells, NK cells and B cells). The present invention provides a method to induce an antitumor immune response through the use of such compositions.
PCT/US1999/021454 1998-10-15 1999-10-14 Methods and compositions to induce antitumor response WO2000022124A3 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US17320398 true 1998-10-15 1998-10-15
US09/173,203 1998-10-15

Publications (2)

Publication Number Publication Date
WO2000022124A2 true WO2000022124A2 (en) 2000-04-20
WO2000022124A3 true true WO2000022124A3 (en) 2000-07-06

Family

ID=22630966

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/021454 WO2000022124A3 (en) 1998-10-15 1999-10-14 Methods and compositions to induce antitumor response

Country Status (1)

Country Link
WO (1) WO2000022124A3 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528088B2 (en) 2002-06-28 2016-12-27 Life Technologies Corporation Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7229621B2 (en) 1998-10-20 2007-06-12 Torrey Pines Institute For Molecular Studies Method to enhance the immunogenicity of an antigen
US7361329B2 (en) 2000-04-21 2008-04-22 Chemocentryx, Inc. Compositions for inducing an immune response
WO2002040044A3 (en) * 2000-11-17 2002-08-22 Immunex Corp Chemoattractant recruitment of dendritic cells for enhancement of immunization
CA2439185A1 (en) 2001-02-23 2002-09-06 Novartis Ag Vector constructs
CN105209054A (en) 2013-04-18 2015-12-30 阿尔莫生物科技股份有限公司 Methods of using interleukin-10 for treating diseases and disorders

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995011984A2 (en) * 1993-10-25 1995-05-04 Canji, Inc. Recombinant adenoviral vector and methods of use
US5677178A (en) * 1993-02-16 1997-10-14 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
WO1998015285A1 (en) * 1996-10-10 1998-04-16 The Wistar Institute Of Anatomy And Biology Methods and compositions for inducing a protective immune response to cancers
WO1998021228A1 (en) * 1996-11-15 1998-05-22 Canji, Inc. Tissue specific expression of retinoblastoma protein
WO1998021330A1 (en) * 1996-11-15 1998-05-22 Indiana University Foundation Exodus chemokine materials and methods
WO1998039464A2 (en) * 1997-03-03 1998-09-11 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
WO1999047169A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Methods to provoke anti-cancer immune responses

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5677178A (en) * 1993-02-16 1997-10-14 Onyx Pharmaceuticals, Inc. Cytopathic viruses for therapy and prophylaxis of neoplasia
WO1995011984A2 (en) * 1993-10-25 1995-05-04 Canji, Inc. Recombinant adenoviral vector and methods of use
WO1998015285A1 (en) * 1996-10-10 1998-04-16 The Wistar Institute Of Anatomy And Biology Methods and compositions for inducing a protective immune response to cancers
WO1998021228A1 (en) * 1996-11-15 1998-05-22 Canji, Inc. Tissue specific expression of retinoblastoma protein
WO1998021330A1 (en) * 1996-11-15 1998-05-22 Indiana University Foundation Exodus chemokine materials and methods
WO1998039464A2 (en) * 1997-03-03 1998-09-11 Cell Genesys, Inc. Adenovirus vectors containing heterologous transcription regulatory elements and methods of using same
WO1999047169A1 (en) * 1998-03-20 1999-09-23 Genzyme Corporation Methods to provoke anti-cancer immune responses

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DIEU M-C ET AL.: "Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 188, no. 2, 20 July 1998 (1998-07-20), pages 373 - 386, XP002133972 *
HE X-S ET AL.: "Construction of adenoviral and retroviral vectors coexpressing the genes encoding the hepatitis B surface antigen and B7-1 protein", GENE, vol. 175, no. 1/2, 10 October 1996 (1996-10-10), pages 121 - 125, XP002041764 *
ISHIDA T ET AL.: "Dendritic cells transduced with wild-type p53 gene elicit potent anti-tumour immune responses", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, vol. 117, no. 2, August 1999 (1999-08-01), pages 244 - 251, XP000891464 *
SHERMAN L A ET AL.: "Strategies for tumor elimination by cytotoxic T lymphocytes", CRITICAL REVIEWS IN IMMUNOLOGY, vol. 18, no. 1-2, 1998, pages 47 - 54, XP000877347 *
SONG W ET AL.: "Dendritic cells genetically modified with and adenovirus vector encoding the cDNA for a model antigen induce protective", JOURNAL OF EXPERIMENTAL MEDICINE, vol. 186, no. 8, 20 October 1997 (1997-10-20), pages 1247 - 1256, XP002133971 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9528088B2 (en) 2002-06-28 2016-12-27 Life Technologies Corporation Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation

Also Published As

Publication number Publication date Type
WO2000022124A2 (en) 2000-04-20 application

Similar Documents

Publication Publication Date Title
Kawarada et al. NK-and CD8+ T cell-mediated eradication of established tumors by peritumoral injection of CpG-containing oligodeoxynucleotides
Le Bon et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon
US20060217328A1 (en) Synergisitic stimulation of the immune system using immunostimulatory oligonucleotides and/or immunomer compounds in conjunction with cytokines and/or chemotherapeutic agents or radiation therapy
Yang et al. Induction of alloreactive cytotoxic T cells by acute virus infection of mice.
Cornelissen et al. The common 5′ terminal sequence on trypanosome mRNAs: a target for anti-messenger oligodeoxynucleotides
GB2338237A (en) In vitro peptide or protein expression library
Ahlers et al. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge
WO2004004743A1 (en) Immunostimulation by chemically modified rna
Baxevanis et al. Compromised anti‐tumor responses in tumor necrosis factor‐α knockout mice
US6949520B1 (en) Methods related to immunostimulatory nucleic acid-induced interferon
Qiao et al. Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors
WO2002014358A3 (en) Novel secreted proteins and their uses
Bellone et al. In vitro priming of cytotoxic T lymphocytes against poorly immunogenic epitopes by engineered antigen‐presenting cells
Abel et al. Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells
WO2001022990A2 (en) Methods related to immunostimulatory nucleic acid-induced interferon
Thomas et al. γδ T cells lyse autologous and allogenic oesophageal tumours: involvement of heat-shock proteins in the tumour cell lysis
Fessenden et al. Studies on polynucleotide-stimulated amino acyl transfer from soluble-RNA to rat liver ribosomes
Zajac et al. Enhanced generation of cytotoxic T lymphocytes using recombinant vaccinia virus expressing human tumor-associated antigens and B7 costimulatory molecules
Yao et al. Th cell-independent immune responses to chimeric hemagglutinin/simian human immunodeficiency virus-like particles vaccine
EP2292771A3 (en) Sense mRNA therapy
WO2003038072A1 (en) Generation and use of new types of dendritic cells
Lui et al. Systemic administration of naked DNA encoding interleukin 12 for the treatment of human papillomavirus DNA-positive tumor
WO2002061076A1 (en) Adiponectin-associated protein
Jung et al. Strong immunogenic potential of a B7 retroviral expression vector: generation of HLA-B7-restricted CTL response against selectable marker genes
Morisaki et al. Characterization and augmentation of CD4+ cytotoxic T cell lines against melanoma

Legal Events

Date Code Title Description
ENP Entry into the national phase in:

Ref country code: AU

Ref document number: 1999 64977

Kind code of ref document: A

Format of ref document f/p: F

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

121 Ep: the epo has been informed by wipo that ep was designated in this application
AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CZ DE DK DM EE ES FI GB GD GE HR HU ID IL IN IS JP KG KR KZ LC LK LR LT LU LV MA MD MG MK MN MX NO NZ PL PT RO RU SE SG SI SK SL TJ TM TR TT TZ UA UZ VN YU ZA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase